These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 28396208)

  • 1. Efficacy of a high potency O
    Fishbourne E; Ludi AB; Wilsden G; Hamblin P; Statham B; Bin-Tarif A; Brocchi E; Grazioli S; Dekker A; Eblé P; King DP
    Vaccine; 2017 May; 35(20):2761-2765. PubMed ID: 28396208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of a high potency O1 Manisa monovalent vaccine against heterologous challenge with foot-and-mouth disease virus of O/SEA/Mya-98 lineage in sheep.
    Singanallur NB; Pacheco JM; Arzt J; Stenfeldt C; Fosgate GT; Rodriguez L; Vosloo W
    Antiviral Res; 2017 Sep; 145():114-122. PubMed ID: 28780422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of cross-protection between O1 Manisa and O1 Campos in cattle vaccinated with foot-and-mouth disease virus vaccine incorporating different payloads of inactivated O1 Manisa antigen.
    Nagendrakumar SB; Srinivasan VA; Madhanmohan M; Yuvaraj S; Parida S; Di Nardo A; Horsington J; Paton DJ
    Vaccine; 2011 Feb; 29(10):1906-12. PubMed ID: 21236232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of a high-potency multivalent foot-and-mouth disease virus vaccine in cattle against heterologous challenge with a field virus from the emerging A/ASIA/G-VII lineage.
    Waters R; Ludi AB; Fowler VL; Wilsden G; Browning C; Gubbins S; Statham B; Bin-Tarif A; Mioulet V; King DJ; Colenutt C; Brown E; Hudelet P; King DP
    Vaccine; 2018 Mar; 36(14):1901-1907. PubMed ID: 29506922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccine strain of O/ME-SA/Ind-2001e of foot-and-mouth disease virus provides high immunogenicity and broad antigenic coverage.
    Lee G; Hwang JH; Park JH; Lee MJ; Kim B; Kim SM
    Antiviral Res; 2020 Oct; 182():104920. PubMed ID: 32828822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective effects of high-potency FMDV O
    Horsington J; Perez CB; Maradei E; Novo SG; Gonzales JL; Singanallur NB; Bonastre P; Vosloo W
    Vaccine; 2017 Sep; 35(38):5179-5185. PubMed ID: 28789849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early protection in sheep against intratypic heterologous challenge with serotype O foot-and-mouth disease virus using high-potency, emergency vaccine.
    Horsington J; Zhang Z; Bittner H; Hole K; Singanallur NB; Alexandersen S; Vosloo W
    Vaccine; 2015 Jan; 33(3):422-9. PubMed ID: 25483241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-protective efficacy of the O1 Manisa + O 3039 bivalent vaccine and the O 3039 monovalent vaccine against heterologous challenge with FMDV O/Jincheon/SKR/2014 in pig.
    Kim T; Hong JK; Oem JK; Lee KN; Lee HS; Kim YJ; Ryoo S; Ko YJ; Park JH; Choi J; Lee SH; Jo HJ; Lee MH; Kim B; Kim J
    Vaccine; 2019 Mar; 37(12):1702-1709. PubMed ID: 30712811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenovirus-vectored foot-and-mouth disease vaccine confers early and full protection against FMDV O1 Manisa in swine.
    Fernandez-Sainz I; Medina GN; Ramirez-Medina E; Koster MJ; Grubman MJ; de Los Santos T
    Virology; 2017 Feb; 502():123-132. PubMed ID: 28039799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of a high potency O1 Manisa monovalent vaccine against heterologous challenge with a FMDV O Mya98 lineage virus in pigs 4 and 7 days post vaccination.
    Wilna V; Hong NT; Geoffrey FT; Jacqueline MM; Jianning W; Van Phuc K; Ngon QV; Phuong le TT; Hung D; Hanh TX; Van Hung V; Anh le TQ; Tien MT; Quang le TV; Long NT; Nagendrakumar SB
    Vaccine; 2015 Jun; 33(24):2778-85. PubMed ID: 25917677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of a high quality O
    Galdo Novo S; Malirat V; Maradei ED; Pedemonte AR; Espinoza AM; Smitsaart E; Lee KN; Park JH; Bergmann IE
    Vaccine; 2018 Mar; 36(12):1570-1576. PubMed ID: 29472132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Vaccine Based on the A/ASIA/G-VII Lineage of Foot-and-Mouth Disease Virus Offers Low Levels of Protection against Circulating Viruses from the A/ASIA/Iran-05 lineage.
    Singanallur NB; Eblé PL; Ludi AB; Statham B; Bin-Tarif A; King DP; Dekker A; Vosloo W
    Viruses; 2022 Jan; 14(1):. PubMed ID: 35062300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emergency FMD Serotype O Vaccines Protect Cattle against Heterologous Challenge with a Variant Foot-and-Mouth Disease Virus from the O/ME-SA/Ind2001 Lineage.
    Singanallur NB; Dekker A; Eblé PL; van Hemert-Kluitenberg F; Weerdmeester K; Horsington JJ; Vosloo W
    Vaccines (Basel); 2021 Sep; 9(10):. PubMed ID: 34696216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of a foot-and-mouth disease vaccine against a heterologous SAT1 virus challenge in goats.
    Lazarus DD; Peta F; Blight D; Van Heerden J; Mutowembwa PB; Heath L; Blignaut B; Opperman PA; Fosgate GT
    Vaccine; 2020 May; 38(24):4006-4015. PubMed ID: 32312581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic and antigenic characterization of serotype O FMD viruses from East Africa for the selection of suitable vaccine strain.
    Lloyd-Jones K; Mahapatra M; Upadhyaya S; Paton DJ; Babu A; Hutchings G; Parida S
    Vaccine; 2017 Dec; 35(49 Pt B):6842-6849. PubMed ID: 29102329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Duration of protection and humoral immunity induced by an adenovirus-vectored subunit vaccine for foot-and-mouth disease (FMD) in Holstein steers.
    Sitt T; Kenney M; Barrera J; Pandya M; Eckstrom K; Warner M; Pacheco JM; LaRocco M; Palarea-Albaladejo J; Brake D; Rieder E; Arzt J; Barlow JW; Golde WT
    Vaccine; 2019 Sep; 37(42):6221-6231. PubMed ID: 31493951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of emergency FMD vaccine antigen payload on protection, sub-clinical infection and persistence following direct contact challenge of cattle.
    Cox SJ; Voyce C; Parida S; Reid SM; Hamblin PA; Hutchings G; Paton DJ; Barnett PV
    Vaccine; 2006 Apr; 24(16):3184-90. PubMed ID: 16488060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An alternate delivery system improves vaccine performance against foot-and-mouth disease virus (FMDV).
    Pandya M; Pacheco JM; Bishop E; Kenney M; Milward F; Doel T; Golde WT
    Vaccine; 2012 Apr; 30(20):3106-11. PubMed ID: 22387223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of ENABL® adjuvant to increase the potency of an adenovirus-vectored foot-and-mouth disease virus serotype A subunit vaccine.
    Barrera J; Schutta C; Pisano M; Grubman MJ; Brake DA; Miller T; Kamicker BJ; Olutunmbi F; Ettyreddy D; Brough DE; Butman BT; Neilan JG
    Vaccine; 2018 Feb; 36(8):1078-1084. PubMed ID: 29358056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant human adenovirus-5 expressing capsid proteins of Indian vaccine strains of foot-and-mouth disease virus elicits effective antibody response in cattle.
    Sreenivasa BP; Mohapatra JK; Pauszek SJ; Koster M; Dhanya VC; Tamil Selvan RP; Hosamani M; Saravanan P; Basagoudanavar SH; de Los Santos T; Venkataramanan R; Rodriguez LL; Grubman MJ
    Vet Microbiol; 2017 May; 203():196-201. PubMed ID: 28619144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.